US skin thickening was also poorly prognostic in all groups but most strongly in TN cancers (53% vs. 80% 6 year survival, p = 0.0004, HR 4.45 (95% CI’s 1.9–10.0), Fig. 3) and less so for HER2 + ve (66% vs. 83% 6 year survival, p = 0.04, HR 2.3 (95% CI’s 1.1–5.0)) and luminal cancers (80% vs. 95% 6 year survival p < 0.0001, HR 23.6 (95% CI’s 9.1–61.3). Here, ERBB2 is linked to cancer.